• Clinical Insights: December 1, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Cytalux™ (pafolacianine) Injection – New Drug Approval – November 29, 2021 – The U.S. Food and Drug Administration approved Cytalux™ (pafolacianine), an imaging drug intended to assist surgeons… Read more »

  • Clinical Insights: November 23, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Voxzogo™ (vosoritide) Injection – New Drug Approval – November 19, 2021 – The U.S. Food and Drug Administration approved Voxzogo™ (vosoritide) injection to improve growth in children five… Read more »

  • Clinical Insights: November 16, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Besremi® (ropeginterferon alfa-2b-njft) Injection – New Drug Approval – November 12, 2021 – The U.S. Food and Drug Administration approved Besremi® (ropeginterferon alfa-2b-njft) injection to treat adults with… Read more »

  • Clinical Insights: November 9, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Scemblix® (asciminib) Tablets – New Orphan Drug Approval – October 29, 2021 – The Food and Drug Administration granted accelerated approval to asciminib (Scemblix®, Novartis AG) for patients… Read more »

  • Clinical Insights: November 2, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Indication/Dosage/Formulation Approval No new update. New/Updated Drug Shortage November 01, 2021 Clobetasol Propionate Topical Solution, 0.05% (Discontinuation) Meloxicam Tablets (Discontinuation) October 29, 2021 Amino… Read more »

  • Clinical Insights: October 26, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Indication/Dosage/Formulation Approval Dupixent® (dupilumab) Injection – New Expanded Indication Approval – October 20, 2021 – The U.S. Food and Drug Administration (FDA) has approved… Read more »

  • Clinical Insights: October 19, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Tavneos™ (avacopan) – New Orphan Drug Approval – October 8, 2021 – ChemoCentryx, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Tavneos™ (avacopan), an… Read more »

  • Clinical Insights: October 12, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Rethymic® (allogeneic processed thymus tissue-agdc) – New Drug Approval – October 8, 2021 – The U.S. Food and Drug Administration approved Rethymic® for the treatment of pediatric patients… Read more »

  • Clinical Insights: October 5, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Formulation Approval No new update. New Indication/Dosage Approval Tecartus® (brexucabtagene autoleucel) Suspension for Intravenous Infusion – New Approved Indication – October 1, 2021 –… Read more »

  • Clinical Insights: September 28, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Opzelura™ (ruxolitinib) Cream – New Drug Approval – September 21, 2021 – Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream for the… Read more »